12 May 2022 by admin in UncategorizedComments Adicet Reports First Quarter 2022 Financial Results and Provides Business Updates
10 May 2022 by admin in UncategorizedComments Arcellx Announces Dosing of First Patient in its Phase 1 Clinical Trial Evaluating ACLX-001, the First Therapeutic in the Dosable and Controllable ARC-SparX Platform, for the treatment of Patients with Relapsed or Refractory Multiple Myeloma
09 May 2022 by admin in UncategorizedComments Design Therapeutics Highlights Clinical and Research Progress and Reports First Quarter 2022 Financial Results
09 May 2022 by admin in UncategorizedComments Arcellx Announces Publication in Blood Advances of Clinical Results from the Dose Escalation Cohorts of its CART-ddBCMA Phase 1 Study in Patients with Relapsed or Refractory Multiple Myeloma
05 May 2022 by admin in UncategorizedComments NextCure Provides Business Update and Reports First Quarter 2022 Financial Results
27 Apr 2022 by admin in UncategorizedComments Tempest Announces Private Placement Financing of $15 Million
19 Apr 2022 by admin in UncategorizedComments Adicet Bio Receives FDA Fast Track Designation for Lead Candidate ADI-001
30 Mar 2022 by admin in UncategorizedComments Design Therapeutics Completes Dosing in First Patient Cohort of Phase 1 Trial of DT-216 GeneTA C TM Molecule for the Treatment of Friedreich Ataxia
29 Mar 2022 by admin in UncategorizedComments Tempest Reports Year End 2021 Financial Results and Provides Business Update
24 Mar 2022 by admin in UncategorizedComments Arcellx Provides Business Update and Reports Fourth Quarter and Year-End 2021 Financial Results
15 Mar 2022 by admin in UncategorizedComments Syros Reports Fourth Quarter and Full Year 2021 Financial Results and Highlights Key Accomplishments and Upcoming Milestones
15 Mar 2022 by admin in UncategorizedComments Adicet Reports Fourth Quarter and Full Year 2021 Financial Results and Highlights Recent Company Progress
10 Mar 2022 by admin in UncategorizedComments Design Therapeutics Reports Pipeline and Business Progress and Fourth Quarter and Full Year 2021 Financial Results
04 Mar 2022 by admin in UncategorizedComments Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
03 Mar 2022 by admin in UncategorizedComments NextCure Provides Business Update and Reports Fourth Quarter and Full Year 2021 Financial Results
28 Feb 2022 by admin in UncategorizedComments Design Therapeutics Announces FDA Clearance of Investigational New Drug Application for First GeneTACTM Molecule for Friedreich Ataxia
16 Feb 2022 by admin in UncategorizedComments Walking Fish Therapeutics Closes $73 Million Series A Financing
08 Feb 2022 by admin in UncategorizedComments Arcellx Announces Closing of Initial Public Offering and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares
02 Feb 2022 by admin in UncategorizedComments Syros Receives FDA Orphan Drug Designation for Tamibarotene for the Treatment of MDS
01 Feb 2022 by admin in UncategorizedComments Design Therapeutics Appoints Drug Development Expert, Jae Kim, M.D., as Chief Medical Officer
10 Jan 2022 by admin in UncategorizedComments Syros Announces Clinical Updates and 2022 Goals to Support its Advancement to a Fully Integrated Biopharmaceutical Company
10 Jan 2022 by admin in UncategorizedComments BioNTech and Crescendo Biologics announce global collaboration to develop multi-specific precision immunotherapies
12 Dec 2021 by admin in UncategorizedComments NextCure and Collaborators Provide Data on Targets in Development at American Society of Hematology Annual Meeting
10 Dec 2021 by admin in UncategorizedComments Adicet Bio, Inc. Announces Closing of $100 Million Public Follow-On Offering and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares
09 Dec 2021 by admin in UncategorizedComments Interius BioTherapeutics Announces Granting of US Patent to Support in Vivo Cell-Specific Gene Delivery Platform
26 Nov 2021 by admin in UncategorizedComments Crescendo Biologics Wins “Best Established Biotech Company” at the 2021 OBN Awards
21 Nov 2021 by admin in UncategorizedComments Zenas BioPharma Acquires Exclusive Worldwide Rights to Obexelimab from Xencor
18 Nov 2021 by admin in UncategorizedComments Tempest Announces First Patient Dosed with TPST-1495 in Combination with Pembrolizumab
18 Nov 2021 by admin in UncategorizedComments Syros Reports Third Quarter 2021 Financial Results and Highlights Key Accomplishments and Upcoming Milestones
18 Nov 2021 by admin in UncategorizedComments Adicet Announces Appointment of Dr. Michael G. Kauffman to the Board of Directors
